ATE253361T1 - AGENTS FOR THE CONTROLLED RELEASE OF PAROXETINE - Google Patents

AGENTS FOR THE CONTROLLED RELEASE OF PAROXETINE

Info

Publication number
ATE253361T1
ATE253361T1 AT96926388T AT96926388T ATE253361T1 AT E253361 T1 ATE253361 T1 AT E253361T1 AT 96926388 T AT96926388 T AT 96926388T AT 96926388 T AT96926388 T AT 96926388T AT E253361 T1 ATE253361 T1 AT E253361T1
Authority
AT
Austria
Prior art keywords
paroxetine
agents
controlled release
release
controlled
Prior art date
Application number
AT96926388T
Other languages
German (de)
Inventor
Graham S Leonard
David P Edler
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10777960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE253361(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE253361T1 publication Critical patent/ATE253361T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96926388T 1995-07-20 1996-07-19 AGENTS FOR THE CONTROLLED RELEASE OF PAROXETINE ATE253361T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9514842.5A GB9514842D0 (en) 1995-07-20 1995-07-20 Novel formulation
PCT/EP1996/003252 WO1997003670A1 (en) 1995-07-20 1996-07-19 Paroxetine controlled release compositions

Publications (1)

Publication Number Publication Date
ATE253361T1 true ATE253361T1 (en) 2003-11-15

Family

ID=10777960

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926388T ATE253361T1 (en) 1995-07-20 1996-07-19 AGENTS FOR THE CONTROLLED RELEASE OF PAROXETINE

Country Status (41)

Country Link
EP (2) EP1382337A1 (en)
JP (2) JP3922392B2 (en)
KR (1) KR100468351B1 (en)
CN (2) CN1117567C (en)
AP (1) AP1052A (en)
AR (1) AR003463A1 (en)
AT (1) ATE253361T1 (en)
AU (1) AU6659196A (en)
BG (1) BG64076B1 (en)
BR (1) BR9609857A (en)
CA (2) CA2445678C (en)
CY (1) CY2408B1 (en)
CZ (1) CZ294110B6 (en)
DE (1) DE69630603T3 (en)
DK (1) DK0839039T4 (en)
DZ (1) DZ2074A1 (en)
EA (2) EA003508B1 (en)
EG (1) EG23934A (en)
ES (1) ES2208757T5 (en)
GB (1) GB9514842D0 (en)
HK (1) HK1010494A1 (en)
HU (1) HU228853B1 (en)
IL (1) IL122940A0 (en)
MA (1) MA23942A1 (en)
MX (1) MX9800571A (en)
MY (1) MY141373A (en)
NO (1) NO315637B1 (en)
NZ (1) NZ315006A (en)
OA (1) OA10652A (en)
PE (1) PE16098A1 (en)
PL (1) PL184987B1 (en)
PT (1) PT839039E (en)
RO (1) RO119119B1 (en)
SI (1) SI0839039T2 (en)
SK (1) SK284117B6 (en)
TR (1) TR199800077T1 (en)
TW (1) TW464513B (en)
UA (1) UA68328C2 (en)
UY (3) UY24288A1 (en)
WO (1) WO1997003670A1 (en)
ZA (1) ZA966148B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
ES2155995T3 (en) 1997-06-10 2001-06-01 Synthon Bv 4-PHENYLPIPERIDINE COMPOUNDS.
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
AU739261B2 (en) 1997-07-01 2001-10-11 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
GB9808479D0 (en) * 1998-04-22 1998-06-17 Smithkline Beecham Plc Method of treatment
CH689805A8 (en) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing it.
US6139875A (en) * 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
ATE311883T1 (en) 1999-03-12 2005-12-15 Aesica Pharmaceuticals Ltd STABLE PHARMACEUTICAL USE FORM FOR PAROXETINE ANHYDRATE
RU2275191C2 (en) * 1999-05-20 2006-04-27 Элан Корпорейшн, Плс Pharmaceutical compositions consisting of multiple particles with sustained-release of serotonin reuptake selective inhibitor
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
ES2159260B1 (en) * 1999-06-22 2002-05-01 Smithkline Beechan Plc NEW PAROXETINE METHANOSULPHONATE COMPOSITION
AU5078700A (en) * 1999-06-22 2001-01-09 Smithkline Beecham Plc Novel composition
ES2162560B1 (en) * 1999-06-25 2002-07-16 Rodriguez Concepcion Pena USE OF FLUOXETINA, PAROXETINA AND OTHER SSRIs FOR THE MANUFACTURE OF MEDICINES IN ORDER TO INCREASE THE CAPACITY OF ABSTENTION OF SUBSTANCES OR ACTIVITIES THAT CREATE DEPENDENCE.
AR030557A1 (en) * 2000-04-14 2003-08-27 Jagotec Ag A TABLET IN MULTI-MAP OF CONTROLLED RELEASE AND TREATMENT METHOD
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
CA2457385A1 (en) * 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
GB2392385A (en) * 2002-09-02 2004-03-03 Cipla Ltd Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
TW200517106A (en) 2003-10-29 2005-06-01 Wyeth Corp Sustained release pharmaceutical compositions
EP1734920A2 (en) * 2004-02-13 2006-12-27 Neuromolecular Inc. Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2005107716A1 (en) * 2004-03-25 2005-11-17 Cadila Healthcare Limited Controlled release paroxetine-containing tablets based on a core and a coating
JP5153629B2 (en) * 2005-08-02 2013-02-27 ルピン・リミテッド Novel controlled release compositions of selective serotonin reuptake inhibitors
KR100591142B1 (en) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 A enteric sustained-release tablet comprising paroxetine
US20090130206A1 (en) * 2006-05-09 2009-05-21 Umesh Nandkumar Khatavkar Controlled Release Compositions of an Antidepressant Agent
KR100885029B1 (en) 2007-02-07 2009-02-23 지엘팜텍 주식회사 An Oral Sustained-Release Triple Layer Tablet
WO2009006299A2 (en) * 2007-06-29 2009-01-08 Dr. Reddy's Laboratories Ltd. Multi-particulate systems
CA2698808A1 (en) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
TW201010743A (en) 2008-09-05 2010-03-16 Otsuka Pharma Co Ltd Pharmaceutical solid preparation
DK2470166T3 (en) * 2009-08-24 2013-09-08 Lundbeck & Co As H NEW COMPOSITIONS OF 1- [2- (2,4-DIMETHYL-PHENYLSULPHANYL) -PHENYL] PIPERAZINE
CN103371982A (en) * 2012-04-20 2013-10-30 王进京 Novel prescription composition and preparation method of paroxetine hydrochloride enteric controlled release tablet
JP2015522047A (en) * 2012-07-09 2015-08-03 ユニリーバー・ナームローゼ・ベンノートシヤープ Photoprotective personal care composition
CN103550182B (en) * 2013-10-29 2015-04-08 吉林省东盟制药有限公司 Enteric-coated sustained release composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
MC2025A1 (en) * 1988-04-20 1990-04-25 Asta Pharma Ag MEDICINAL PRODUCT CONTAINING AZELASTINE AND CAPABLE OF RELEASING IT IN A CONTROLLED WAY
IT1237904B (en) * 1989-12-14 1993-06-18 Ubaldo Conte CONTROLLED SPEED RELEASE TABS OF ACTIVE SUBSTANCES
JPH0436237A (en) * 1990-06-01 1992-02-06 Taiho Yakuhin Kogyo Kk Composite antitumor preparation
DK0497956T3 (en) * 1990-08-21 1996-08-12 Theratech Inc Controlled release preparations
EP0558679A1 (en) * 1990-11-24 1993-09-08 BEECHAM GROUP plc Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
HUT69390A (en) * 1991-05-07 1995-09-28 Dynagen Inc Controlled, sustained release delivery system for smoking cessation
JPH05139964A (en) * 1991-11-14 1993-06-08 Takada Seiyaku Kk Enteric preparation of mexiletine hydrochloride
ES2168290T3 (en) * 1993-11-23 2002-06-16 Euro Celtique Sa METHOD FOR PREPARING A SUSTAINED RELEASE COMPOSITION.
IT1274241B (en) * 1993-12-03 1997-07-15 Smithkline Beecham Farma THERAPEUTIC AGENT / POLYMER MATRIX COMPLEXES EQUIPPED WITH IMPROVED FLAVOR CHARACTERISTICS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
MX9707585A (en) * 1995-04-03 1997-12-31 Abbott Lab Homogeneous mixtures of low temperature-melting drugs and additives for controlled release.

Also Published As

Publication number Publication date
UY26242A1 (en) 2001-01-31
AP9801177A0 (en) 1998-01-31
SI0839039T1 (en) 2004-04-30
UA68328C2 (en) 2004-08-16
JP3922392B2 (en) 2007-05-30
JP2006265258A (en) 2006-10-05
BG102259A (en) 1998-09-30
DE69630603T3 (en) 2008-01-03
AR003463A1 (en) 1998-08-05
MA23942A1 (en) 1997-04-01
KR19990029076A (en) 1999-04-15
CA2445678A1 (en) 1997-02-06
EA200100022A1 (en) 2001-06-25
AP1052A (en) 2002-03-21
EP1382337A1 (en) 2004-01-21
SI0839039T2 (en) 2007-10-31
UY24288A1 (en) 1997-01-16
OA10652A (en) 2002-09-18
EA003508B1 (en) 2003-06-26
EP0839039B1 (en) 2003-11-05
CA2227298A1 (en) 1997-02-06
IL122940A0 (en) 1998-08-16
CA2227298C (en) 2003-12-09
EP0839039B2 (en) 2007-06-06
SK284117B6 (en) 2004-09-08
PL324553A1 (en) 1998-06-08
PL184987B1 (en) 2003-01-31
WO1997003670A1 (en) 1997-02-06
DE69630603T2 (en) 2004-09-23
JPH11509539A (en) 1999-08-24
BG64076B1 (en) 2003-12-31
CZ294110B6 (en) 2004-10-13
KR100468351B1 (en) 2005-03-16
MX9800571A (en) 1998-04-30
HUP9900299A2 (en) 1999-09-28
CN1282456C (en) 2006-11-01
UY24436A1 (en) 2001-08-27
DZ2074A1 (en) 2002-07-22
HK1010494A1 (en) 1999-06-25
MY141373A (en) 2010-04-16
CN1515257A (en) 2004-07-28
TW464513B (en) 2001-11-21
NO315637B1 (en) 2003-10-06
ES2208757T3 (en) 2004-06-16
BR9609857A (en) 1999-03-16
EA199800140A1 (en) 1998-10-29
NZ315006A (en) 2000-01-28
TR199800077T1 (en) 1998-05-21
HUP9900299A3 (en) 1999-11-29
AU6659196A (en) 1997-02-18
DE69630603D1 (en) 2003-12-11
EA003775B1 (en) 2003-08-28
ZA966148B (en) 1998-01-19
NO980240D0 (en) 1998-01-19
GB9514842D0 (en) 1995-09-20
NO980240L (en) 1998-01-20
CY2408B1 (en) 2004-09-10
CA2445678C (en) 2009-11-24
EP0839039A1 (en) 1998-05-06
CN1117567C (en) 2003-08-13
EG23934A (en) 2008-01-14
ES2208757T5 (en) 2007-12-16
PT839039E (en) 2004-03-31
DK0839039T3 (en) 2004-03-08
RO119119B1 (en) 2004-04-30
PE16098A1 (en) 1998-04-16
DK0839039T4 (en) 2007-10-08
CN1195986A (en) 1998-10-14
CZ18398A3 (en) 1998-06-17
HU228853B1 (en) 2013-06-28
SK5398A3 (en) 1998-07-08

Similar Documents

Publication Publication Date Title
ATE253361T1 (en) AGENTS FOR THE CONTROLLED RELEASE OF PAROXETINE
DE69522843T2 (en) bone anchor
DE69836304D1 (en) Device for the prevention of atrial fibrillation
ATE235236T1 (en) UNSUBSTITUTED POLYDIALLYLAMINES FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
DE59712720D1 (en) Device for the controlled emergency stop of lifts
DE59608798D1 (en) ENDOPARASITICIDAL AGENTS
DE69603089D1 (en) COMPOSITION FOR TREATING MASONRY
DK0880892T5 (en) Controlled release agents
DE69520235D1 (en) ANTI-SWEATANT AGENTS
DE59500266D1 (en) Transdermal therapeutic system for the application of naloxone
DE69721756T2 (en) PAROXETINE FOR TREATING DEPRESSION
DE59600130D1 (en) Device for the care of broken bones
DE69834937D1 (en) ANTIBIOTICS FOR THE TREATMENT OF STOMACHES
ATA167097A (en) DEVICE FOR THE PERSONALIZATION OF PEOPLE
ATE346840T1 (en) AMINOALKYLPHENOL DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND MEMORY DISORDER
DE69834799D1 (en) Device for restricting the movement of loads
DE59607463D1 (en) DEVICE FOR CONTROLLING AREAS
DE69806062D1 (en) COMBINATION THERAPY FOR TREATING AIDS
KR960026478U (en) Fracture
DE59607862D1 (en) Device for working floors
DE29502722U1 (en) Device for the care of broken bones
ATE253366T1 (en) USE OF 7-APHA-METHYL-17-ALPHA-ETHYNYL-ESTRANE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLERosis
DE29605796U1 (en) Device for preventing the settling of living things
DE29515946U1 (en) Device for preventing the settling of living things
EE9900404A (en) Method for the preparation of arylaminotriazolopyridines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0839039

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 0839039

Country of ref document: EP